|Assessment process complete
|For the management of adult patients with severe chronic/acute pain.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Assessment Recommended.
|Full pharmacoeconomic assessment commissioned by HSE
|NCPE assessment completed
|NCPE assessment outcome
Tapentadol (Palexia®) may be considered cost-effective but should be reserved for patients who cannot tolerate existing strong oral opioids.